Palmer, D. H., Symeonides, S. N., Dempsey, F. C., Crichton, S., Tennant, C., Wood, C., Yule, L., Iftikhar, S., Proudfoot-Jones, J., Kielak, M., Blagden, S. P. (2026). MDX-124, a first-in-class annexin-A1 targeting antibody, in patients with locally advanced or metastatic solid malignancies: Data supporting RP2D from the dose escalation stage of a first-in-human phase Ib trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.e15112